Sarilumab

• Rheumatoid arthritis (moderate-to-severe)
• Second-line treatment after inadequate DMARD response
• Alternative to TNF inhibitors
• Monotherapy when methotrexate is not tolerated
• Combination therapy with conventional DMARDs

Sarilumab is a fully human monoclonal antibody that blocks the interleukin-6 receptor, used to treat moderately to severely active rheumatoid arthritis in adults whose disease has not responded adequately to conventional disease-modifying antirheumatic drugs. By interrupting IL-6 signaling — a central pathway in synovial inflammation, joint destruction, and many of the systemic features of RA — sarilumab reduces joint pain and swelling, slows radiographic progression, and improves physical function. It is one of two IL-6 receptor antagonists in clinical use, alongside tocilizumab, and represents an important option in the modern musculoskeletal treatment landscape for patients with rheumatoid arthritis.

Mechanism of Action

Interleukin-6 is a pleiotropic cytokine produced by macrophages, T cells, B cells, fibroblasts, and synoviocytes. In rheumatoid arthritis, IL-6 is markedly elevated in synovial fluid and serum, where it drives synovial cell proliferation, recruits leukocytes to inflamed joints, stimulates osteoclast differentiation that erodes bone, induces hepatic synthesis of acute-phase reactants such as C-reactive protein and serum amyloid A, suppresses albumin production, promotes anemia of chronic inflammation by inducing hepcidin, and contributes to the fatigue, low-grade fever, and weight loss many RA patients experience.

Sarilumab is a high-affinity human IgG1 monoclonal antibody that binds both soluble and membrane-bound IL-6 receptor alpha (sIL-6R and mIL-6R), preventing IL-6 from forming the signaling complex with gp130 that initiates intracellular JAK-STAT and MAPK pathways. By blocking IL-6 signaling at the receptor level, sarilumab dampens the entire downstream cascade — synovial inflammation, joint destruction, acute-phase response, hepcidin-mediated anemia, and systemic constitutional symptoms — within weeks of initiation. C-reactive protein typically falls to undetectable levels within days to weeks. The drug is administered subcutaneously and reaches peak plasma concentrations 2 to 4 days after injection. Steady-state concentrations are achieved after 12 to 16 weeks of every-2-week dosing. The half-life is dose-dependent, ranging from 2 to 10 days at therapeutic levels.

Clinical Use

Sarilumab is FDA-approved for adults with moderately to severely active rheumatoid arthritis who have had inadequate response or intolerance to one or more conventional synthetic DMARDs such as methotrexate, sulfasalazine, hydroxychloroquine, or leflunomide. American College of Rheumatology guidelines, available at rheumatology.org, position biologic and targeted synthetic DMARDs as second-line therapy after conventional DMARD failure, with TNF inhibitors traditionally favored as the initial biologic choice. IL-6 receptor antagonists, JAK inhibitors such as tofacitinib or upadacitinib, and other biologics with different mechanisms are alternatives for TNF non-responders.

Sarilumab can be used as monotherapy or in combination with methotrexate or other conventional DMARDs. Monotherapy is particularly useful for patients who cannot tolerate methotrexate due to nausea, hepatotoxicity, or pulmonary side effects — a meaningful clinical advantage compared with TNF inhibitors, which generally show better outcomes when combined with methotrexate. Pivotal trials demonstrated superior ACR20, ACR50, and ACR70 response rates compared with placebo and showed inhibition of radiographic progression. Direct comparison with adalimumab monotherapy demonstrated superiority for sarilumab on multiple outcome measures. Choice among biologics depends on prior treatment, comorbidities, dosing preference, and insurance coverage. Patients with concurrent giant cell arteritis, JIA-related conditions, or castleman disease may favor IL-6 pathway blockade over other mechanisms.

How to Take It

Sarilumab is supplied in 150 mg/1.14 mL and 200 mg/1.14 mL prefilled syringes and prefilled pen autoinjectors for subcutaneous administration. The standard dose is 200 mg every 2 weeks, with reduction to 150 mg every 2 weeks for management of laboratory abnormalities such as neutropenia, thrombocytopenia, or transaminase elevation. Some clinicians initiate at 150 mg in patients with relatively low body weight, advanced age, or higher infection risk, then titrate upward based on response and tolerability.

Injections are given in the front of the thigh, the abdomen at least 2 inches from the navel, or the upper outer arm. Sites should be rotated with each dose to minimize reactions. The medication requires refrigeration at 36°F to 46°F (2°C to 8°C) but should be allowed to warm to room temperature for 30 minutes before injection — cold injections sting more and may absorb less reliably. Do not shake or freeze. If a dose is missed and it has been less than 4 days, give the dose immediately and resume the regular schedule; if more than 4 days have passed, give the dose at the next scheduled time. Patients can be trained to self-inject after instruction by a clinician. The first 2 to 4 weeks may bring mild injection-site soreness or transient flu-like symptoms; significant clinical improvement in joint symptoms typically begins within 4 to 12 weeks.

Monitoring and Follow-Up

Laboratory monitoring is more important for sarilumab than for many other biologics. Baseline assessment includes complete blood count with differential, comprehensive metabolic panel including liver enzymes (ALT, AST, alkaline phosphatase, bilirubin), lipid panel, hepatitis B and C serology, and tuberculosis screening with interferon-gamma release assay or PPD plus chest X-ray. Vaccinations including influenza, pneumococcal (PCV15/20 and PPSV23), and shingles should be brought up to date before initiation since live vaccines must be avoided during therapy.

During the first year, complete blood count and ALT should be checked 4 to 8 weeks after initiation and then every 3 months. Sarilumab is not started if the absolute neutrophil count is below 2000/mm³ or platelets are below 150,000/mm³. ALT or AST elevations above 3 times the upper limit of normal call for dose interruption; persistent elevation above 5 times ULN warrants discontinuation. Lipid panel should be rechecked at 4 to 8 weeks and then periodically — IL-6 inhibition characteristically raises LDL and total cholesterol, which may require statin therapy. Disease activity should be monitored with a validated tool such as DAS28 or CDAI at every visit. Annual TB re-screening is appropriate for patients with risk factors. The American College of Rheumatology guidelines provide additional monitoring detail.

Special Populations

Elderly patients can be treated with sarilumab, but baseline infection risk and the higher prevalence of diverticular disease (a risk factor for the rare but serious complication of gastrointestinal perforation) warrant careful assessment. No dose adjustment is needed for mild to moderate renal or hepatic impairment; sarilumab has not been studied in severe impairment. Pregnancy data are limited; IgG monoclonal antibodies cross the placenta, particularly in the second and third trimesters. Live vaccines should be deferred in infants exposed in utero for at least 6 months after birth. Use during pregnancy weighs maternal disease control against potential fetal exposure.

Sarilumab is excreted in breast milk in animals; human data are sparse. Discussion with both rheumatology and obstetrics is warranted. Pediatric safety and efficacy have not been established for adult RA indications. Patients with chronic infections such as tuberculosis or hepatitis B reactivation risk require pre-treatment management. Prior history of diverticulitis is a relative contraindication; intestinal perforation has been reported, often without typical warning symptoms because IL-6 blockade suppresses fever and acute-phase response.

When to Contact Your Doctor

Seek emergency care for severe abdominal pain — IL-6 blockade can mask the typical fever and inflammatory signs of intestinal perforation, so any new severe or worsening abdominal pain in a patient on sarilumab requires urgent evaluation regardless of how well they feel otherwise. High fever, shaking chills, productive cough, painful urination, or any sign of infection deserves prompt attention because the immunosuppressive effect of sarilumab plus the suppressed acute-phase response can hide serious infection until late. Persistent unexplained cough, night sweats, or weight loss may suggest tuberculosis reactivation.

Yellowing of the skin or eyes, dark urine, or persistent fatigue may signal hepatotoxicity. Easy bruising, prolonged bleeding, or unusual fatigue may reflect cytopenias. Sudden swelling of the face, tongue, or throat after injection requires emergency care for possible anaphylaxis. New mouth ulcers, persistent diarrhea, or any signs of opportunistic infection warrant prompt review. Pregnancy or planning pregnancy should be discussed before continuing or stopping therapy.

For expert evaluation of rheumatoid arthritis treatment options including biologics such as sarilumab, contact us or schedule a visit with the Zimmer Medical Group team to develop a tailored plan.